Chimerix loss widens in 4Q

Mar. 07, 2014 @ 06:32 PM

Chimerix loss widens in 4Q

The company’s revenues were down 75 percent to $879,000 in the quarter due to a decrease in reimbursable expenses associated with an ongoing contract with the Biomedical Advanced Research and Development Authority.

The company reported the larger loss was primarily due to the decrease in revenues from the contract along with an increase in general and administrative expenses.  

The company is in the testing phase for an antiviral candidate designed to prevent cytomegalovirus in recipients of bone marrow transplants.

“We are enthusiastic about brincidofovir's potential to prevent clinically significant viral infections in bone marrow transplant recipients, and look forward to expanding the compound's development activities to other DNA viruses and other patient populations,” Kenneth I. Moch, president and CEO of Chimerix, said in a news release.